21:05 , Mar 25, 2019 |  BC Extra  |  Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
01:31 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million on Feb. 26 in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through...
14:01 , Feb 26, 2019 |  BC Extra  |  Financial News

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million Tuesday in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA...
17:47 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Axsome's AXS-05 meets in Phase II for MDD

Axsome Therapeutics Inc. (NASDAQ:AXSM) added $4.24 (161%) to $6.87 on Jan. 7 after reporting that AXS-05 met the primary endpoint in the Phase II ASCEND trial to treat moderate-to-severe major depressive disorder (MDD). On the...
22:03 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting inflammatory macrophages could help treat Type II diabetes-associated pain. In a mouse model of Type II diabetes, the macrophage-targeting immunotoxin Mac1-saporin decreased disease-induced mechanical allodynia compared with vehicle. Also...
20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Adenocarcinoma; brain cancer; lung cancer; neuroendocrine tumors Cell culture studies identified a nicotonic acetylcholine receptor α7 (CHRNA7) antagonist that could help treat glioblastoma, lung adenocarcinoma and neuroblastoma. Chemical synthesis and cell-based testing of structural...
19:10 , Oct 26, 2018 |  BC Week In Review  |  Company News

Stanford launches cannabinoid company Katexco for inflammatory disorders

Stanford University professors launched Katexco Pharmaceuticals Corp. (Toronto, Ontario) to develop therapies that target endocannabinoid and nicotine receptors to treat inflammatory diseases. Katexco has exclusively licensed IP from the university. The IP was generated by...
16:36 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

Oyster Point Pharma Inc. (Princeton, N.J.) said all three doses of OC-01 met the primary endpoint of improving tear production in the Phase IIb ONSET trial to treat dry eye disease. The company also reported...
13:07 , Oct 24, 2018 |  BC Extra  |  Clinical News

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

Oyster Point Pharma Inc. (Princeton, N.J.) said all three doses of OC-01 met the primary endpoint of improving tear production in the Phase IIb ONSET trial to treat dry eye disease. The company also reported...
20:19 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not...